03.09.2015 • TopicsPerstorpCorbionSustainability

Corbion and Perstorp Develop Joint Product

Swedish speciality chemicals firm Perstorp and Dutch biotechnology firm Corbion have jointly developed a new lactide caprolactone copolymer for hot melt adhesives.

The fully compostable copolymer is said to have renewable content of more than 80%, which allows adhesive manufacturers to serve the increasing demand for sustainable products and address food safety concerns in packaging.

The material will offer good performance and allow formulators to remain competitive, the companies said. It is expected to be commercially available during the fourth quarter of 2015.

Marco Bootz, Corbion’s senior vice-president biochemicals said: "This new material represents the culmination of two years' joint development work with Perstorp. It will create a strong technology platform for the development of polymers, which provide a genuine alternative to traditional technologies for the adhesive industry."

The breakthrough innovation for adhesives is part of an agreement signed by the companies in 2011.

Perstorp innovation vice-president Håkan Björnberg said: "Through this partnership, we supply adhesives manufacturers with a competitive advantage by providing safe, innovative technologies that deliver high performance with a reduced environmental footprint."

Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.

Virtual Event

Digitalization in the Chemical Industry
CHEManager Spotlight

Digitalization in the Chemical Industry

Save the Date: October 22, 2025
The event will be promoted to a combined audience of over 100,000 professionals across Europe through the CHEManager and CITplus networks.

most read

Photo
14.05.2025 • TopicsPharma

Pharma Outlook 2025

The environment for pharma in 2025 is diverse and challenging: New treatment options are being brought to market in ever shorter cycles.